We Are Leaders In Antibody and Peptide Discovery
Originally formed in 2008 to exploit the macrocyclic Cyclotide plant microprotein family as a therapeutic or delivery scaffold using phage display libraries.

Cyclogenix Technology expanded into:
  • Fully Human phage scFv antibody libraries
  • Large Cyclotide scaffold & VNAR single domain libraries
  • Filings on half-life extension IP, specific oral availability/BBB transfer sequences
Our current research focus:
  • Oral delivery (metabolic/cardiovascular)
  • BBB agent bioavailability (stroke/neurodegenerative)
  • Multispecifics (oncology)


The Team